mc4r

MC4R (melanocortin 4 receptor)

MC4R is a class-A G-protein-coupled receptor (GPCR) expressed primarily in the paraventricular nucleus (PVN) of the hypothalamus, where it serves as the canonical effector of the central leptin-melanocortin pathway for energy homeostasis. Loss-of-function mutations in MC4R are the most common monogenic cause of severe human obesity (~1–5% of cases); gain-of-function variants protect against obesity, type 2 diabetes, and coronary artery disease. Setmelanotide (Imcivree, FDA-approved 2020) is an MC4R agonist approved for monogenic MC4R-pathway-deficiency obesity. In the aging context, MC4R is most relevant to the deregulated-nutrient-sensing hallmark through its role in appetite regulation and energy expenditure, and to the emerging literature on anorexia of aging and cachexia.

Identity

• UniProt: P32245 (MC4R_HUMAN)
• NCBI Gene: 4160
• HGNC: 6932 (symbol: MC4R)
• Ensembl: ENSG00000166603
• Genomic location: Chromosome 18q21.32 (single exon; no introns — uncommon for GPCRs)
• Length: 332 amino acids; molecular weight ~36.9 kDa
• Mouse ortholog: Mc4r (one-to-one; high sequence conservation)

Structure and biochemistry

MC4R is a 7-transmembrane GPCR (rhodopsin family, class A). Key structural features:

• Seven transmembrane helices — characteristic of all melanocortin receptors (MC1R–MC5R)
• N-linked glycosylation — three sites in the N-terminal extracellular domain; required for proper trafficking to cell surface
• S-palmitoylation — Cys-318 (C-terminal tail); anchors the tail to the inner leaflet, influencing receptor trafficking and G-protein coupling
• Disulfide bonds — multiple intra- and (reported) inter-subunit; the receptor can form homodimers though the functional significance is unclear
• No introns — single exon gene, unusual among GPCRs; makes frameshift mutations particularly impactful (truncating the entire receptor)

Signaling

MC4R is primarily coupled to Gαs: agonist binding raises intracellular cAMP via adenylyl cyclase activation, driving PKA-mediated phosphorylation cascades that suppress appetite and increase energy expenditure ¹.

A secondary β-arrestin–mediated arm has been described and is therapeutically important. Lotta et al. 2019 found that naturally occurring human MC4R gain-of-function variants with β-arrestin signaling bias (but not cAMP bias alone) confer protection against obesity, T2D, and CAD — suggesting the β-arrestin pathway is the metabolically productive one ². This finding has implications for next-generation agonist design.

Inverse agonist / constitutive activity: MC4R has significant constitutive (ligand-independent) Gαs activity. AgRP (Agouti-related peptide) acts as an inverse agonist — suppressing basal cAMP below constitutive levels — rather than a simple competitive antagonist. This constitutional activity means that even partial loss-of-function from heterozygous mutations reduces total signaling capacity meaningfully.

Ligands

Ligand	Type	Source
α-MSH (ACTH 1-13)	Endogenous agonist (high affinity)	alpha-msh — POMC cleavage product, arcuate POMC neurons
β-MSH	Endogenous agonist	POMC cleavage product
γ-MSH	Weaker agonist (MC3R-preferring)	POMC cleavage
ACTH (1-39)	Agonist	Pituitary corticotropes
AgRP	Inverse agonist	Arcuate AgRP/NPY neurons
Setmelanotide	Synthetic agonist (FDA-approved)	setmelanotide (stub)
Melanotan II	Synthetic pan-MC agonist (unapproved)	Non-selective; also MC1R/MC3R/MC5R

Expression and tissue distribution

• Primary: PVN hypothalamus — the central satiety node. MC4R-expressing PVN neurons project to brainstem autonomic centers and regulate both food intake and sympathetic outflow to brown adipose tissue.
• Other CNS: Cortex, hippocampus, amygdala, brainstem dorsal vagal complex. Distribution explains non-metabolic effects (MC4R agonism raises heart rate / blood pressure — a key clinical liability of setmelanotide).
• Peripheral (minor): Gut enteroendocrine cells, adipocytes (low expression). Peripheral expression is orders of magnitude lower than hypothalamic; physiological significance is debated.

Function

MC4R is the primary integrator of long-range energy-status signals in the CNS:

1. Appetite suppression — α-MSH from arcuate POMC neurons activates PVN MC4R → cAMP → reduces orexigenic neuropeptide release → decreased food intake.
2. Energy expenditure — MC4R signaling increases sympathetic outflow to brown adipose tissue, raising thermogenesis and resting metabolic rate. Mc4r-null mice are obese but also cold-intolerant.
3. Glucose homeostasis — independent of adiposity, MC4R mutations worsen insulin sensitivity; part of the reason why MC4R loss-of-function produces hyperinsulinemia disproportionate to fat mass.
4. Cardiovascular tone — MC4R agonism raises heart rate and blood pressure via sympathetic activation. This is an on-target liability of agonist therapy, not an off-target side effect.

MC4R and monogenic obesity

Loss-of-function (LoF) MC4R mutations are the most common cause of monogenic severe obesity in humans ³:

• Prevalence in severely obese cohorts: ~5.8% in pediatric severe obesity (Farooqi et al. 2003, n=500); 1–5% in adult severe-obesity cohorts depending on cutoffs.
• Inheritance: codominant — heterozygous carriers have intermediate BMI elevation; homozygous/compound-heterozygous individuals have severe childhood-onset obesity, hyperphagia, and hyperinsulinemia. This contrasts with most Mendelian obesity genes where only homozygotes are affected.
• Phenotype: hyperphagia (increased meal size), increased linear growth (hyperinsulinemic), normal fasting leptin per fat mass, no adrenal insufficiency (distinguishes from POMC deficiency).
• Over 200 unique LoF variants identified; frameshift, nonsense, and missense mutations that impair surface trafficking, Gs coupling, or ligand binding all produce the phenotype.
• needs-replication — population prevalence estimates vary substantially by diagnostic criteria and cohort ascertainment strategy; the 5.8% figure from Farooqi 2003 may overestimate community prevalence.

Gain-of-function variants: Lotta et al. 2019 (n=~452,300 UK Biobank participants; n=~0.5 million including additional replication cohorts) identified naturally occurring GoF MC4R variants (n=9) that activate both Gαs and β-arrestin pathways ². Carriers of β-arrestin-biased GoF alleles had lower BMI (β=−0.39 kg/m² per allele, p=2×10⁻⁴²), lower odds of obesity (OR 0.81 per allele), up to 50% lower risk of obesity (2-allele carriers), lower T2D risk (OR 0.88), and lower CAD risk (OR 0.94). The cardiometabolic protection was driven by variants with β-arrestin signaling bias — variants with cAMP bias alone (without β-arrestin bias) did not protect against T2D or CAD. β-arrestin recruitment explained 88% of the variance in BMI associations across MC4R variants (R²=0.88, p=3×10⁻⁵).

Therapeutics

Setmelanotide (Imcivree)

Setmelanotide is a cyclic heptapeptide MC4R agonist (ring structure analogous to Melanotan II but optimized for MC4R selectivity and β-arrestin engagement). FDA-approved November 25, 2020 (NDA213793 ORIG-1) for:

• POMC deficiency obesity
• PCSK1 deficiency obesity
• LEPR deficiency obesity

Expanded June 16, 2022 (SUPPL-1) to add:

• Bardet-Biedl syndrome obesity

Phase 3 evidence: In open-label trials of POMC/LEPR-deficient patients, setmelanotide achieved ≥10% bodyweight loss in 80% of POMC-deficient and ~45% of LEPR-deficient participants ⁴. no-fulltext-access — these figures could not be independently verified against the primary PDF (closed-access paper). In a randomized placebo-controlled trial of Bardet-Biedl syndrome and Alström syndrome (n=38 enrolled: 32 BBS + 6 Alström), 32.3% (95% CI 16.7–51.4%; p=0.0006) of patients ≥12 years in the full analysis set achieved ≥10% bodyweight reduction after 52 weeks on setmelanotide vs 0% on placebo — all responders had BBS ⁵.

Safety: Most common adverse effects are injection-site reactions, nausea, hyperpigmentation (on-target MC1R effect), and sexual adverse effects (spontaneous erection in males — same MC4R mechanism as Melanotan II’s best-known property). Clinically important: blood pressure elevation from sympathetic MC4R activation. BP monitoring is required.

Early proof-of-concept: Collet et al. 2017 demonstrated setmelanotide was ~10–500-fold more potent than α-MSH at rescuing signaling by mutant MC4Rs in cell-based assays, and conducted a randomized double-blind placebo-controlled Phase 1b trial (28 days; n=6 MC4R-heterozygous carriers on setmelanotide, n=2 placebo; plus n=41 obese controls) showing significant weight loss in the MC4R-deficient arm (mean −3.48 kg, p<0.0001 vs baseline) without BP or HR elevation ⁶.

Other development programs: Multiple MC4R agonists are in development for broader obesity indications (not just monogenic). As of 2026-05-09, 4 active/recruiting trials (ClinicalTrials.gov: NCT06760546, NCT06772597, NCT05774756, NCT05093634) evaluate setmelanotide in congenital hypothalamic obesity, Prader-Willi syndrome, and related conditions.

Druggability-tier rationale

Tier 1 — an FDA-approved drug (setmelanotide) targets MC4R directly and is used for a genetic obesity indication that centrally involves the same receptor. The aging-context tier-1 is appropriate: MC4R agonism is validated as a pharmacological modality in humans; whether it applies to aging-specific appetite decline (anorexia of aging) is an unanswered question that does not degrade the tier. No aging-indication approval exists.

Aging context

Anorexia of aging and cachexia

Age-associated involuntary weight loss — the “anorexia of aging” — is a major contributor to sarcopenia and frailty. The melanocortin system may be involved:

• POMC neuron activity in the arcuate nucleus, and thus α-MSH release to PVN MC4R, may be tonically elevated or dysregulated in aged rodents — potentially contributing to reduced appetite-drive restoration after fasting. The mechanism is not established in humans. needs-human-replication unsourced
• Cancer cachexia and chronic-disease cachexia involve elevated melanocortin system tone; MC4R antagonists have been proposed as anti-cachexia agents, though none is FDA-approved.
• AgRP/NPY neurons — which oppose MC4R activation — appear to decline in function with age in some rodent models, potentially biasing the system toward greater MC4R activation and reduced orexigenic tone. needs-human-replication

Hallmark linkage

MC4R links to the deregulated-nutrient-sensing hallmark as follows: the leptin-melanocortin axis is a canonical nutrient-sensing relay (leptin → arcuate POMC/AgRP → MC4R PVN → appetite + expenditure). Age-associated leptin resistance, reduced POMC neuron sensitivity, and potential MC4R signaling shifts all represent failures of nutrient-sensing regulation. MC4R does not directly intersect with mTORC1, AMPK, or sirtuins, but converges on insulin-igf1 signaling through its effects on insulin sensitivity and hyperinsulinemia in LoF carriers.

Dimension	Status
Pathway conserved in humans?	yes — POMC/MC4R axis is highly conserved mammals
Phenotype (obesity, appetite) conserved?	yes — human LoF mutation phenotype mirrors Mc4r-null mice
Aging-specific changes replicated in humans?	no — primarily rodent data for age-MC4R dynamics

MR evidence

Partial — MC4R LoF variants are well-established GWAS hits for obesity and BMI. Mendelian randomization studies using MC4R locus instruments have been conducted for obesity-related endpoints (BMI, T2D, CAD). The Lotta 2019 study used a population-genetics approach with n~452,300 (UK Biobank) that is MR-adjacent (variant stratification by functional consequence), demonstrating causal protective effects of β-arrestin-biased GoF variants on metabolic disease ². A formal two-sample MR for aging-specific outcomes (frailty, longevity, sarcopenia) has not been published as of 2026-05-09. partial reflects: GWAS instruments exist and have been deployed for metabolic-disease MR; aging-specific MR not yet attempted.

Pathway membership

• melanocortin-system — the central leptin → POMC → α-MSH → MC4R → PVN → appetite/expenditure axis
• pomc-processing — upstream biosynthesis and processing of MC4R’s primary endogenous ligand
• camp-signaling — primary downstream second-messenger cascade
• insulin-igf1 — convergent metabolic regulation; MC4R mutations produce hyperinsulinemia and insulin resistance

Key interactors

• alpha-msh — primary endogenous agonist; POMC-derived; released from arcuate POMC neurons
• AgRP — endogenous inverse agonist; released from arcuate AgRP/NPY neurons; competes with α-MSH at MC4R and suppresses constitutive activity
• MRAP2 (Melanocortin Receptor Accessory Protein 2) — modulates MC4R surface expression and signaling; MRAP2 mutations cause obesity in mice and have been identified in human severe obesity cohorts unsourced

Limitations and gaps

• No MC4R wiki page for melanocortin-system pathway — this pathway does not yet have an atomic page; linked as implicit stub.
• setmelanotide — no compound page yet; stub implied by link.
• camp-signaling — no pathway page; implicit stub.
• Aging-specific data is almost entirely rodent — the hypothesis that MC4R dysregulation contributes to anorexia of aging lacks human mechanistic validation. needs-human-replication
• MRAP2 interaction needs a primary citation before the interactor claim can be confirmed. unsourced
• β-arrestin pathway selectivity — whether setmelanotide vs next-generation β-arrestin-biased agonists differ in aging-relevant outcomes is unknown. no-mechanism
• GTEx aging correlation cannot be computed for hypothalamic MC4R due to tissue scarcity in GTEx. needs-tissue-expression-data
• Formal aging-outcome MR not yet published. needs-replication

Footnotes

Footnotes

1. doi:10.1530/JOE-18-0596 · Baldini G & Phelan KD · J Endocrinol 2019 · review · model: CNS melanocortin circuit · synthesises evidence on POMC/AgRP/MC4R neuron circuit, Gs-cAMP signaling mechanism, and therapeutic implications for genetic obesity ↩

2. doi:10.1016/j.cell.2019.03.044 · Lotta LA et al. (Lotta, Mokrosinski, Farooqi) · Cell 2019 · n=~452,300 UK Biobank (BMI n=450,708); ~0.5 million including replication cohorts · population-genetics/functional-variant-stratification · model: human GWAS + HEK293 cell-based assays · 61 MC4R variants characterised; 9 GoF, 47 LoF · GoF variants with β-arrestin signaling bias: OR 0.81 obesity (p=3×10⁻³⁸), OR 0.88 T2D (p=4×10⁻⁶), OR 0.94 CAD (p=0.02); β-arrestin recruitment explained 88% of BMI-association variance · cAMP-biased GoF without β-arrestin bias did not protect against T2D/CAD ↩ ↩² ↩³

3. doi:10.1056/NEJMoa022050 · Farooqi IS et al. (Farooqi, Keogh, Yeo, Lank, Cheatham, O’Rahilly) · NEJM 2003 · n=500 probands with severe early-onset obesity (recruited from 750 subjects; first consecutive 500 unrelated probands) · observational + in-vitro functional assay · model: human pediatric severe obesity cohort (UK, GOOS study) · 29/500 (5.8%) had pathogenic MC4R mutations (23 heterozygous, 6 homozygous); codominant inheritance — heterozygotes 68% prevalence of early-onset obesity; homozygotes all severely obese; subjects with residual receptor signaling had less severe phenotype ↩

4. doi:10.1016/S2213-8587(20)30364-8 · Clément K et al. (Clément, Kühnen) · Lancet Diabetes Endocrinol 2020 · n=21 (POMC/LEPR-deficient) · open-label phase 3 · model: human monogenic obesity · ≥10% weight loss in 80% POMC-deficient and ~45% LEPR-deficient participants · NOT VERIFIED: closed-access (not_oa per a local paper archive); numerics sourced from secondary literature no-fulltext-access ↩

5. doi:10.1016/S2213-8587(22)00277-7 · Haqq AM et al. (Haqq, Argente) · Lancet Diabetes Endocrinol 2022 · n=38 enrolled (32 BBS + 6 Alström); double-blind, randomised, placebo-controlled phase 3 + open-label period · rct · 32.3% (95% CI 16.7–51.4%; p=0.0006) of patients ≥12 years achieved ≥10% bodyweight reduction after 52 weeks setmelanotide vs 0% placebo; all responders had BBS · verified via PMC9847480 (local PDF download failed) ↩

6. doi:10.1016/j.molmet.2017.06.015 · Collet TH et al. (Collet, Farooqi, Van der Ploeg) · Mol Metab 2017 · randomised double-blind placebo-controlled phase 1b RCT (28 days) + in-vitro · n=6 MC4R-heterozygous on setmelanotide, n=2 placebo, n=41 obese controls · model: human MC4R-deficient patients + HEK293 cell-based assay · setmelanotide ~10–500× more potent than α-MSH at mutant MC4Rs; significant weight loss (−3.48 kg vs baseline, p<0.0001) and waist circumference reduction in MC4R-deficient arm; no BP/HR elevation ↩